Dear Sir, Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held on ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Omkar Pharmachem Ltd approved unaudited financial results for the quarter and half-year ended 30 September 2025 on 14 November 2025. The company reported nil revenue from operations, with 'other operating income' of Rs. 13.50 lakhs in Q2 and Rs. 27.00 lakhs in H1 FY26, broadly flat versus the same period last year. However, total expenses rose sharply to Rs. 17.06 lakhs in H1 (vs Rs. 13.26 lakhs in H1 FY25), driven mainly by higher employee costs and other expenses. Profit before tax fell to Rs. 10.38 lakhs (H1 FY26) from Rs. 13.74 lakhs (H1 FY25), and profit after tax nearly halved to Rs. 7.74 lakhs versus Rs. 13.74 lakhs earlier. The auditor (Dipal R. Shah & Co.) issued a clean limited review report with no qualifications. The company remains debt-free with negative other equity of Rs. -57.27 lakhs.
Weakening profitability: PAT has fallen roughly 44% in H1 FY26 despite flat income, signalling margin pressure from rising costs. Negative other equity and negligible core operations make this a micro-cap stock to watch closely, though the clean auditor report and zero debt limit near-term solvency risk.